Krystal Biotech announces FDA clearance of IND application for KB408

Krystal Biotech announced that the U.S. Food and Drug Administration, FDA, cleared the Investigational New Drug Application, IND, for KB408 for the treatment of alpha-1 antitrypsin deficiency, AATD. “We are excited to advance KB408, our investigational gene therapy for patients with alpha-1 antitrypsin deficiency, into the clinic in our Serpentine-1 study,” said Hubert Chen, M.D., Senior Vice President of Clinical Development at Krystal Biotech. Dr. Chen continued, “This IND acceptance represents an important milestone for us as we work to address a serious lung disease with limited treatment options, and also allows us to demonstrate the potential of our platform to deliver genes repeatedly to epithelial cells of the lung.”